FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular, to an isolated caninised antibody for treating cancer associated with expression of the canine programmed death receptor 1 (canine PD-1). Also disclosed are a nucleic acid encoding the light and heavy chains of said antibody, an expression vector containing said nucleic acid, a pharmaceutical composition containing said antibody.
EFFECT: invention allows for effective treatment of canine diseases associated with expression of PD-L1.
8 cl, 10 tbl, 13 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTIBODIES TO CANINE INTERLEUKIN-4 ALPHA RECEPTOR | 2016 |
|
RU2736732C2 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| ANTIBODIES OF DOGS WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2687209C1 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
